(COG ANBL0032) Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue

The primary objective of this study is to determine if monoclonal antibody CH14.18 +cytokinews+isotretinoin improves event free survival after myeloablative therapy and stem cell rescue as compared to RA alone, in high risk neuroblastoma pts who have achieved a pre-ASCT response of CR, VGPR, or PR.

Study Number: 

NCG 63405

Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.